PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420392
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420392
Duchenne Muscular Dystrophy (DMD), a genetic disorder that leads to muscle degeneration, continues to affect individuals worldwide. While the condition is primarily X-linked recessive, it can also be inherited from parents or caused by new mutations. Despite numerous therapies and drugs to manage DMD, there is currently no cure for this debilitating disease.
Factors Driving the Global Duchenne Muscular Dystrophy Market
Focus on Early Intervention and Last-Stage Patients
Drug developers are increasingly concentrating on developing therapies targeting newborns, young infants, and even patients in the last stages of DMD. Over the past few years, there has been rapid development in DMD therapeutics. However, a significant portion of patients still cannot benefit from available treatments due to their high cost and lack of awareness.
Corticosteroids Leading the Way
Among the various products available for DMD treatment, corticosteroids are expected to lead the market. By the end of 2026, corticosteroids are projected to surpass US$ 9,000 million in revenue. Scientific research indicates that corticosteroids can improve muscle strength for up to two to five years, although the long-term benefits remain uncertain.
Hospital Pharmacies as Key Distribution Channels
Hospital pharmacies are poised to be the largest distribution channel for DMD treatments between 2024 and 2031. The increasing hospitalization of DMD patients and government investments in healthcare infrastructure are contributing to the growth of hospital pharmacies.
Mutation Suppression Therapy Gaining Favor
Mutation suppression therapy is becoming a highly preferred treatment option for DMD. By 2026, it is projected to generate over US$ 6,000 million in revenue. This therapy targets specific mutations responsible for DMD, offering potential benefits to patients. Several mutation suppression therapies are undergoing clinical trials, with some on the verge of FDA approval.
Regional Trends
Europe is anticipated to emerge as a leading region in the global DMD market by 2026. North America and the Asia Pacific Excluding Japan (APEJ) are also expected to experience robust growth between 2024 and 2031.
Key Players in the Global DMD Market
Prominent companies in the global Duchenne Muscular Dystrophy market include ITALFARMACO S.p.A., FibroGen, Inc., Summit Therapeutics plc, PTC Therapeutics, Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.
Market Segmentation
Product Type
Distribution Channel
Therapy
Region